Pipeline of new drugs to fight superbugs is ‘worryingly thin’, experts warn
#superbugs #antibiotics #drug pipeline #antimicrobial resistance #public health #infection #innovation #investment
📌 Key Takeaways
- Experts warn the pipeline for new antibiotics to combat superbugs is dangerously limited.
- The lack of new drugs increases risks from antibiotic-resistant infections.
- Urgent investment and innovation are needed to address this public health threat.
- Current antimicrobial resistance (AMR) trends could lead to more deaths and healthcare burdens.
📖 Full Retelling
<p>UK’s GSK is leading the way in research but AstraZeneca is not involved in the area, report finds</p><ul><li><p><a href="https://www.theguardian.com/business/live/2026/mar/10/oil-price-drops-stocks-rebound-trump-iran-war-end-market-news">Business live – latest updates</a></p></li></ul><p>The pipeline of drugs to fight superbugs remains “worryingly thin” and has shrunk by 35% in the last five years, experts have warned, predicti
🏷️ Themes
Public Health, Antibiotic Resistance
Entity Intersection Graph
No entity connections available yet for this article.
Original Source
<p>UK’s GSK is leading the way in research but AstraZeneca is not involved in the area, report finds</p><ul><li><p><a href="https://www.theguardian.com/business/live/2026/mar/10/oil-price-drops-stocks-rebound-trump-iran-war-end-market-news">Business live – latest updates</a></p></li></ul><p>The pipeline of drugs to fight superbugs remains “worryingly thin” and has shrunk by 35% in the last five years, experts have warned, predicti
Read full article at source